Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−0.18CNY
−70.70 MCNY
1.29 BCNY
165.27 M
About NANJING VAZYME BIOTECH
Sector
Industry
CEO
Lin Cao
Website
Headquarters
Nanjing
Founded
2012
ISIN
CNE100004ZK3
FIGI
BBG00YPHTNW3
Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. Its products include Biological reagents and In vitro diagnostic products. The biological reagents products consist of polymerase chain reaction series, molecular cloning series, reverse record series, gene sequencing series, bio-assay series, and cell and protein series. The In vitro diagnostic products encompass point-of-care testing diagnostic reagents and instrument. The company was founded on March 16, 2012 and is headquartered in Nanjing, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 688105 is 26.52 CNY — it has increased by 2.83% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange NANJING VAZYME BIOTECH stocks are traded under the ticker 688105.
NANJING VAZYME BIOTECH is going to release the next earnings report on Apr 26, 2024. Keep track of upcoming events with our Earnings Calendar.
688105 stock is 5.08% volatile and has beta coefficient of 1.34. Check out the list of the most volatile stocks — is NANJING VAZYME BIOTECH there?
688105 earnings for the last quarter are −0.07 CNY per share, whereas the estimation was 0.17 CNY resulting in a −141.27% surprise. The estimated earnings for the next quarter are 0.09 CNY per share. See more details about NANJING VAZYME BIOTECH earnings.
NANJING VAZYME BIOTECH revenue for the last quarter amounts to 298.00 M CNY despite the estimated figure of 308.39 M CNY. In the next quarter revenue is expected to reach 403.39 M CNY.
Yes, you can track NANJING VAZYME BIOTECH financials in yearly and quarterly reports right on TradingView.
688105 stock has risen by 7.50% compared to the previous week, the month change is a 13.92% rise, over the last year NANJING VAZYME BIOTECH has showed a 24.01% decrease.
688105 net income for the last quarter is 7.02 M CNY, while the quarter before that showed 4.70 M CNY of net income which accounts for 49.20% change. Track more NANJING VAZYME BIOTECH financial stats to get the full picture.
Today NANJING VAZYME BIOTECH has the market capitalization of 10.31 B, it has decreased by 4.09% over the last week.
Yes, 688105 dividends are paid annually. The last dividend per share was 1.25 CNY. As of today, Dividend Yield (TTM)% is 4.85%. Tracking NANJING VAZYME BIOTECH dividends might help you take more informed decisions.
Like other stocks, 688105 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NANJING VAZYME BIOTECH stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NANJING VAZYME BIOTECH technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NANJING VAZYME BIOTECH stock shows the sell signal. See more of NANJING VAZYME BIOTECH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NANJING VAZYME BIOTECH future price: according to them, 688105 price has a max estimate of 35.72 CNY and a min estimate of 35.72 CNY. Read a more detailed NANJING VAZYME BIOTECH forecast: see what analysts think of NANJING VAZYME BIOTECH and suggest that you do with its stocks.